Skip to main content

Table 2 Association between EGFR T790 M mutation and clinical features in patients with disease progression after receiving 1st generation EGFR TKI treatment

From: EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors

  EGFR T790M detected by any method EGFR T790M detected by plama ctDNA ddPCR T790M detected by cobas plama ctDNA test Cobas Activating Mutation SQI Cobas T790M SQI ddPCR T790M quantitative
Characteristics Total Mutant Wild type P Mutant Wild type P Mutant Wild type P Mean P Mean P Mean P
Gender
 Male 23 12 11 1 11 12 0.864 2 12 0.7 10.24 0.859 9.81 0.101 0.52 0.307
 Female 46 24 22 21 25 8 25 10.55 8.17 1.4
Smoking status
 Smoker 22 11 11 0.805 10 12 0.916 3 11 1 10.59 0.897 9.8 0.472 1.63 0.384
 Non-smoker 47 25 22 22 25 7 26 10.37 7.94 0.86
Clinical Stage
 IIIB 20 9 11 0.495 6 14 0.176 2 12 0.003 9.24 0.444 7.8 0.77 0.29 0.033
 IVA 21 10 11 10 11 0 15 10.03 NA 0.2
 IVB 28 17 11 16 12 8 10 11.51 8.68 2.37
M Stage
 M1a 19 9 10 0.627 9 10 0.827 0 15 0.004 10.03 0.541 NA NA 0.21 0.178
 M1b 4 2 2 2 2 0 1 NA NA 1.07
 M1c 26 16 10 15 11 8 9 11.51 8.5 2.4
Time of EGFR-TKI treatment
  ≤ 6 months 14 6 8 0.733 6 8 0.952 1 6 0.621 10.5 0.082 8.99 0.203 0.83 0.472
 6–12 months 26 14 12 12 14 5 12 12.71 10.32 1.75
 >12 months 29 16 13 14 15 4 19 8.86 6.11 0.67
  1. ddPCR Droplet Digital PCR, SQI Semi-Quantitative Index, Bold numbers showing statisticaly significant results